1.3 thiazole Derivatives, inhibitors of DNA gyrase and topoisomerase IV / or

摘要

It also describes the process of preparing these drugs, the pharmaceutical ingredients that contain them, how they are used as drugs, and how they are used to treat bacterial infections. Claim 1: a compound classified as formula (1): (I) R1 is Cl, R2 is br or CF, R3 is CH3, (II) R1 is br, R2 is Cl, Br, CN or CF3, R3 is CH3, (III) R1 is CN, R2 is br or CF3, R3 is CH3, or (IV) R1 is CH3, R2 and R3 are CL; R4 is h, fluoride, methyl, methoxi, etoxi, cycloxi, proposxi, aliloxi and benloxi; R5 is hydrogen or C1-4 tar; y = n or CRA, where RA is h, CH3, F, CF3 or CN; R6 is selected from any 1-4 tar, halogen-1-4 alquiniloc2-4, alquiniloc2-4,C3-6cycloalkyl, (cycloalkylC3-6) alkyl, (C1-4alkoxy) alkyl, (cycloalkoxyC3-6) alkyl, (haloalkoxyC1-4) alkyl, N- (C1-4alkyl) alkyl, N, N- ( C1-4alkyl) 2alkyl, carbocyclyl-R7- or heterocyclyl-R8; R7 and R8 are independently selected from a direct bond, -O-,-N (R9) --C (O) --N (R10) C (O) --C (O) N (R11) --S (O) p--SO2N (R12) - o -N (R13) SO2-In this case, R9, R10, R11, R12 and R13 are independently selected from hydrogen or hydrocarbon 1-4 and p; their salts are pharmaceutically acceptable.